ImmunityBio expands ATM equity offering capacity by $460M; authorized shares increased by 300M

ImmunityBio, Inc.

Amendment to ATM agreement with Jefferies LLC authorizes up to $459.97M in additional common stock sales.
Board and stockholders approved increase in authorized common shares from 1.35B to 1.65B, effective Nov 10, 2025.
ATM sales will be made under existing S-3ASR shelf registration and prospectus supplement dated Dec 23, 2025.
Amendment also updates settlement to T+1 and modifies auditor comfort letter delivery requirements.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ImmunityBio, Inc. amended Amendment No. 1 with Jefferies LLC valued at $459,972,480 (effective 2025-12-23).

Action: amendment
Agreement: atm program
Counterparty: Jefferies LLC
Value: $459,972,480
Effective: 2025-12-23

Exact text from the filing

On December 23, 2025, ImmunityBio, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment to Sale Agreement”) to the Open Market Sale Agreement SM dated April 30, 2021, (the “Sale Agreement”) with Jefferies LLC (the “Agent”) relating to the sale and issuance of shares of its common stock, par value $0.0001 per share (the “Shares”), from time to time through an “at the market” offering program under which the Agent acts as the Company’s sales agent.

View on SEC.gov

306 material agreements filed in the last 30 days. Browse all material agreements →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-331244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.